TRIFLUSAL VERSUS ASPIRIN IN SECONDARY STROKE PREVENTION:RESULTS OF TACIP STUDY
TACIP was a multicentre, double-blind, randomised, parallel trial comparing the efficacy and safety of triflusal (600 mg/od) and ASA (325 mg/od) in patients who had a recent TIA or non disabling stroke. The primary end-point was the combined occurrence of non-fatal stroke, non-fatal AMI or cardiovascular death. Any of them separately was a secondary end-point, as well as total mortality, major systemic or cerebral hemorrhage and systemic thromboembolism. Forty-three centres in Spain and Portugal participated in the trial. A total of 2108 patients were evaluated with a mean follow-up of 31 months. There were no significant differences between both groups regarding to baseline characteristics. Main results were: The incidence of major and minor hemorrhages were higher in ASA than in triflusal group (24.5% vs 16.4%; p<0.001). Conclusion: Triflusal and low-dose ASA have a similar efficacy in secondary stroke prevention. Major and minor hemorrhages were significantly reduced by triflusal. Triflusal is a safer alternative to aspirin in the secondary prevention of stroke.